


MYCN copy number tied to poor features in neuroblastoma

July 24 2017



(HealthDay)—The rate of unfavorable features is increased in

association with increasing *MYCN* copy number in patients with neuroblastoma, according to a study published online July 11 in *Cancer*.

Kevin Campbell, M.D., from Harvard Medical School in Boston, and colleagues conducted a retrospective study involving [patients](#) with *MYCN* wild-type tumors, *MYCN* gain (two- to four-fold increase), or high-level *MYCN* amplification (MNA; more than four-fold increase). The authors examined ordered associations between *MYCN* copy number category and features of interest.

The researchers found that 79.1 percent of the 4,672 patients had *MYCN* wild-type tumors, 2.8 percent had *MYCN* gain, and 18.1 percent had MNA. The percentage of patients with an unfavorable feature was lowest, intermediate, and highest in the *MYCN* wild-type, the *MYCN* gain, and the MNA categories, respectively (P *MYCN* gain category). Inferior event-free survival and overall survival were seen for patients with *MYCN* gain compared with *MYCN* wild-type. *MYCN* gain correlated with the lowest response rate after chemotherapy among patients with high-risk disease. A significantly increased risk for death was seen among patients with non-stage 4 disease and patients with non-high-risk disease with *MYCN* [gain](#).

"Increasing *MYCN* copy number is associated with an increasingly higher rate of unfavorable clinical/biological [features](#), with 11q aberration being an exception," the authors write.

More information: [Abstract](#)
[Full Text \(subscription or payment may be required\)](#)

Copyright © 2017 [HealthDay](#). All rights reserved.

Citation: *MYCN* copy number tied to poor features in neuroblastoma (2017, July 24) retrieved 1

May 2024 from <https://medicalxpress.com/news/2017-07-mycn-tied-poor-features-neuroblastoma.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.